• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Namesystem, laser, fiber optic, photodynamic therapy
Generic Namesystem, laser, fiber optic, photodynamic therapy
5 canewood industrial park
st michael BB110
PMA NumberP940010
Supplement NumberS011
Date Received09/13/2013
Decision Date03/21/2014
Product Code
MVG[ Registered Establishments with MVG ]
Advisory Committee General & Plastic Surgery
Supplement Typereal-time process
Supplement Reason change design/components/specifications/material
Expedited Review Granted? No
Combination Product Yes
Approval Order Statement 
Approval for:1) a change in the material of the tubing cap placed over the diffuser tip from a polycarbonatematerial to an etfe tubing material;2) the use of heat bonding for the etfe tubing material in place of the adhesive bonding presently used for the tubing cap;3) elimination of the orange sheath presently added over the inactive length of the presentlymarketed fiber optic diffusers; and4) modification of the diffuser tip, specifically:a) use of a silver mirror to replace the dielectric material presently used;b) the use of a silicon diffuser mix between the end of the fiber core and dielectric mirror;c) and the addition of diffuser shrink tubing to the distal end. The device, as modified, will be marketed under the trade name optiguide fiber optic diffuserdcyl 700 series and is indicated for use in photodynamic therapy with photofrin(porfimer sodium) for injection for: 1) palliation of patients with completely obstructing esophageal cancer or patients with partiallyobstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorilytreated with nd:yag laser therapy;2) reduction of obstruction and palliation of symptoms in patients with completely or partiallyobstructing endobronchial nonsmall cell lung cancer (nsclc);3) treatment of microinvasive endobronchial nsclc in patients for whom surgery and radiotherapy are not indicated; and4) ablation of high-grade dysplasia (hgd) in barretts esophagus (be) among patients who are not candidates for esophagectomy.